Oncoinvent to present and attend the 32nd Annual Congress of the European Association of Nuclear Medicine

Oncoinvent announces that Radspherin® research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).

The presentation is entitled:

Alpha-Emitting Radiopharmaceutical for IP Therapy of Peritoneal Metastases: In Vitro Evaluation and Therapeutic Effects in a Murine Model

Authors:  T. B. Bønsdorff, E. Napoli, I. S. Jorstad, S. Westrøm, Ø. S. Bruland, R. H. Larsen

Session: EP-55 - Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development - Preclinical and translational aspects - Preclinical aspects - Animal models and in-vitro studies

Abstract No.: EP-0788

Format: Electronic poster

For further information, please contact:

Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer 
Cell: +47 41 28 71 79 
Email: nordby@oncoinvent.com

About Radspherin®

Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies. 

About Oncoinvent

Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to explore and develop multiple technological avenues before selecting a lead product candidate for preclinical testing.